Venatorx Pharmaceuticals develops anti-infectives to treat multi-drug-resistant bacterial infections and viral infections.
Venatorx Pharmaceuticals has raised $24.7M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2022.
Venatorx Pharmaceuticals's investors include Abingworth, Foresite Capital, BioAdvance, Wellcome Trust, Versant Ventures.
Venatorx Pharmaceuticals is headquartered in Malvern, United States.
Venatorx Pharmaceuticals develops anti-infectives to treat multi-drug-resistant bacterial infections and viral infections.
Venatorx Pharmaceuticals is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Venatorx Pharmaceuticals — Funding & Investors." VCBacked, September 2, 2022, https://www.vcbacked.co/company/venatorx-pharmaceuticals. Accessed October 1, 2026.
VCBacked. (2022). Venatorx Pharmaceuticals — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/venatorx-pharmaceuticals
{{cite web |title=Venatorx Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/venatorx-pharmaceuticals |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated